PTC Therapeutics Inc. (NASDAQ: PTCT) is experiencing significant momentum within the biotechnology sector following a surge in its stock price to a 52-week high of $40.69. This increase reflects heightened investor confidence driven by the positive clinical outcomes of its Friedreich ataxia (FA) investigational treatment, vatiquinone. Over the past year, the company’s share value has […]
PTC Therapeutics, Inc. has announced a significant step forward in its mission to combat phenylketonuria (PKU) by receiving FDA acceptance for the New Drug Application (NDA) of Sepiapterin. The acceptance of this NDA, supported by positive clinical trial results, brings much-needed hope to patients managing this rare metabolic disorder. The FDA’s action sets a critical […]
PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering $1.5 billion from the Evrysdi royalty stream. The terms dictate Royalty Pharma’s acquisition of additional Evrysdi royalties worth $1 billion upfront. The deal comes with provisions for future sales, where PTC could part with all its retained […]
US-based PTC Therapeutics has secured marketing approval in Russia for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The approval for Translarna has been given by the Ministry of Health of the Russian Federation for Duchenne muscular dystrophy caused by a nonsense mutation in patients, aged two years and older. Stuart […]
In a major strategic move, US biopharmaceutical company PTC Therapeutics has finalized its acquisition of Agilis Biotherapeutics, a biotech firm specializing in the development of gene therapies for rare genetic disorders affecting the central nervous system (CNS). The acquisition, valued at $200 million, includes a mix of $50 million in cash and approximately $150 million […]